Walgreens connected care: impact of managed therapy on adherence to medications used to treat XXXX and related comorbid conditions.

@entity1 @entity308 @entity15 @entity1295
BACKGROUND: The Walgreens Connected Care @entity15 (CCMS) treatment management program provides enhanced levels of monitoring, oversight, and care for @entity1 taking MS disease-modifying agents. This study compared rates of adherence to MS medications for @entity1 participating in the CCMS program for at least 6 months with those for @entity1 participating for less than 6 months. For a subsample of @entity1 , we also examined the relationship between adherence and the presence of @entity1295 or @entity308 . METHODS: This was a retrospective study of @entity1 new to the CCMS program and followed up for 1 year of participation. Adherence to MS medications was measured as the proportion of days covered, with propensity scores used to match the CCMS intervention group to the less-managed comparison group. The impact of program participation on the relationship between @entity308 or @entity1295 and adherence over time was a separate analysis. RESULTS: Mean proportion of days covered rates improved significantly in the group managed for at least 6 months compared with those who were less managed. Positive screenings for @entity1295 and @entity308 reduced adherence in the less-managed group but not in @entity1 with longer participation in the program. CONCLUSIONS: Overall, the CCMS program significantly increased adherence to MS medications. This improved adherence was not negatively impacted by positive screenings for @entity1295 and @entity308 .
